Siemens Healthineers Atellica TSTII 睾酮检测在 CDC HoSt-TT 项目中的评估
本研究评估 Atellica IM TSTII 睾酮检测是否符合 CDC HoSt-TT 认证标准,并与 ID-LC-MS/MS 对比。结果显示该检测平均偏倚在 ±6.4% 内,与 LC-MS/MS 相关性好(r ≥ 0.98),计算游离睾酮与平衡透析/LC-MS/MS 相关性良好(r = 0.965),获 HoSt-TT 认证。
要点
- Atellica TSTII 获 CDC HoSt-TT 认证,与 LC-MS/MS 比对平均偏倚在 ±6.4% 内。
- 该检测重复性 CV 2.18%,室内精密度 CV 3.46%,总分析误差 18.3%。
- 计算游离睾酮与平衡透析/LC-MS/MS 相关性良好(slope=0.9530,r=0.965)。
核心结论
- TSTII 检测获 CDC HoSt-TT 认证,与 LC-MS/MS 比对一致性强,计算游离睾酮与平衡透析/LC-MS/MS 相关性好。
- LC-MS/MS 仍是睾酮定量的参考方法,尤其在低浓度时,但 HoSt 认证支持 TSTII 在特定分析和临床情境下用于女性和儿童。
研究设计与样本
- 研究分析 Atellica IM TSTII 的分析性能,并使用 HoSt-TT 认证样本进行方法比对,按性别分层。
- 使用残留患者样本比较 TSTII 总睾酮与 LC-MS/MS,并比较计算游离睾酮(Vermeulen 法,ISSAM 计算器)与实测游离睾酮。
主要发现
- HoSt-TT 与 Atellica IM TSTII 结果平均偏倚在 ±6.4% 内,OLS 回归斜率 1.02-1.06,r ≥ 0.98。
- TSTII 重复性 2.18% CV,室内精密度 3.46% CV,总分析误差 18.3%(IQR 11.6-31.6%)。
- TSTII 总睾酮与 LC-MS/MS 比对(患者样本)斜率 0.9798,r = 0.991;计算游离睾酮与平衡透析/LC-MS/MS 斜率 0.9530,r = 0.965。
关键数值与推荐
- HoSt-TT 与 TSTII 平均偏倚在 ±6.4% 内,OLS 回归斜率 1.02-1.06,r ≥ 0.98。
- TSTII 重复性 2.18% CV,室内精密度 3.46% CV,总分析误差 18.3%(IQR 11.6-31.6%)。
- TSTII 与 LC-MS/MS 比对斜率 0.9798,r = 0.991;计算游离睾酮与平衡透析/LC-MS/MS 斜率 0.9530,r = 0.965。
临床怎么用
- TSTII 获 CDC HoSt-TT 认证,可在特定分析和临床情境下用于女性和儿童睾酮测量。
- LC-MS/MS 仍是睾酮定量参考方法,低浓度时尤其应优先采用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standardized testosterone measurement is essential for diagnosing hypogonadism, infertility, endocrine disorders, and monitoring therapy. The CDC Hormone Standardization Program for Total Testosterone (HoSt-TT) evaluates assay performance against ID-LC-MS/MS using clinically relevant concentrations. This study assesses the Atellica IM TSTII assay compliance to HoSt-TT criteria and its correlation with LC-MS/MS. METHODS: Analytical performance of Atellica IM TSTII and method comparison studies using HoSt-TT certification samples were analyzed, evaluated, and stratified by sex. Comparisons of TSTII TT to LC-MS/MS and calculated vs measured free testosterone (FT) were performed and analyzed using remnant patient samples, with FT calculated (Vermeulen method, ISSAM calculator). RESULTS: HoSt-TT vs Atellica IM TSTII assay results demonstrated average bias within ±6.4%, with OLS regression slopes of 1.02-1.06, r ≥ 0.98. TSTII demonstrated repeatability (2.18% CV), within-lab precision (3.46% CV), and overall total analytical error of 18.3% (IQR 11.6-31.6%). Furthermore, comparing TT on the TSTII to LC-MS/MS (LDT) using native patient samples, resulted in strong fits (slope = 0.9798, r = 0.991); and calculated FT correlated well with equilibrium dialysis/LC-MS/MS (slope = 0.9530, r = 0.965). CONCLUSION: The TSTII assay is CDC HoSt-TT certified, has strong alignment to LC-MS/MS, and shows good correlation of calculated FT with equilibrium dialysis/LC-MS/MS. Although LC-MS/MS remains the reference method for testosterone quantification, particularly at low concentrations, CDC HoSt certification of the TSTII assay supports its potential suitability for measuring testosterone concentrations in women and children within defined analytical and clinical contexts.
引用
- Li J, Isaacs SD, Pagliaro S, et al. Evaluation of the Siemens Healthineers Atellica TSTII testosterone assay in the CDC HoSt-TT program. J Clin Endocrinol Metab. 2026. PMID: 41712433. doi:10.1210/clinem/dgag071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。